New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 14, 2014
09:18 EDTSNE, ENZY, ISIS, PTX, FOSL, CLDX, MM, RUBI, TTWO, SODA, P, BMY, GSK, CSIQ, PLUGOn The Fly: Pre-market Movers
HIGHER: Pernix Therapeutics (PTX), up 42% after acquiring TREXIMET tablets for migraine from GlaxoSmithKline (GSK)... Isis Pharmaceuticals (ISIS), up 9.6% after Phase 2 results for ISIS-GCGR for diabetes reported... Canadian Solar (CSIQ), up 1.7% after partnering with Ikea to build 3.6MW solar systems... Pandora (P), up 1.4% following upgrade at Raymond James... Rubicon Project (RUBI), up 22% after upgraded at Oppenheimer and RBC Capital following its Q1 earnings report... Celldex (CLDX), up 10.5% after announcing collaboration agreement with Bristol-Myers (BMY)... Millennial Media (MM), up 3.4% after CEO Barrett purchases 291K shares. LOWER: Sony (SNE), down 5.6% after reporting FY13 results, guiding to losses in FY14... DOWN AFTER EARNINGS: Fossil (FOSL), down 6.5%... Enzymotec (ENZY), down 8.6%... Plug Power (PLUG), down 6.6%... SodaStream (SODA), down 3.2%... Take-Two (TTWO), down 3.5%.
News For SNE;P;CLDX;PLUG;SODA;FOSL;CSIQ;TTWO;PTX;GSK;RUBI;ISIS;BMY;MM;ENZY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>
November 11, 2014
15:25 EDTFOSLNotable companies reporting after market close
Subscribe for More Information
14:14 EDTFOSLFossil November weekly 103 straddle priced for 7.6% move into Q3
Subscribe for More Information
14:10 EDTFOSLFossil technical remarks ahead of results
In the prior three months the shares have underperformed the broader averages, trading up 1%. The trading range has been similar to that of the past six months, with the range largely contained between $95 at the low and $105 at the high. Shares are trading close to the range high. If the news is strongly positive, there could be a breakout above that $105 area. Next upside objectives based on resistance levels would be at $108.08 and $111.20. The latter level is particularly important technically as it is the top of the bearish gap down from May. A breakout above that level would put the shares back on a more bullish footing longer-term, with next resistance at $116.31. Upside would likely additionally be fueled by the large short-base in the name at over 12.7% of the float short on stronger than expected results or guidance. If the news fails to move shares higher, or is a disappointment, the recent uptrend off the mid-October low would likely be broken. Support would be at $99.44, $95, and $91.84 which is the 52-week low.
09:36 EDTPTXPernix Therapeutics initiated with an Outperform at Avondale
Target $20.
08:41 EDTENZYEnzymotec initiates clinical study of Vayarin
Enzymotec announced the initiation of a clinical study to evaluate the efficacy of Vayarin in adults with Attention Deficit Hyperactivity Disorder, or ADHD. The randomized, double-blind, placebo-controlled study will enroll 171 patients between the ages of eighteen and fifty-five. This will be a multi-center study in the United States, including the NYU School of Medicine. The study was designed to assess the efficacy of Vayarin in adults with ADHD, measured primarily by the ADHD Investigator Symptom Rating Scale.
November 10, 2014
16:28 EDTCLDXOncothyreon, Celldex announce initiation of ONT-10, varlilumab clinical trial
Oncothyreon Inc. (ONTY) and Celldex Therapeutics (CLDX) announced that they have initiated a combined clinical trial of ONT-10 and varlilumab. ONT-10 is a therapeutic vaccine targeting the tumor-associated antigen MUC1. Varlilumab is a fully human monoclonal antibody that targets CD27, a critical molecule in the activation pathway of lymphocytes. The trial is an open-label Phase 1b study of ONT-10 administered at the recommended single agent dose in combination with varlilumab at two dose levels in up to 42 patients with advanced breast or ovarian cancer. The primary objective of the trial is to determine the safety and tolerability of the combined therapy. Additional objectives include evaluations of the impact of combination treatment on MUC1-specific humoral and cellular immune responses, T-cell activation markers and levels of regulatory T-cells, and anti-tumor effects. The Phase 1b trial will be conducted by Oncothyreon under the terms of a previously announced collaboration agreement between Oncothyreon and Celldex. The two companies will jointly own the data from the trial and will make any plans for potential future development of the combination therapy together. Under the agreement, neither company has granted the other a license, or any other rights, to its product candidate.
16:07 EDTGSKUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
16:07 EDTISISIsis Pharmaceuticals files to sell $425M in convertible senior notes due 2021
Subscribe for More Information
16:02 EDTPLUGPlug Power appoints Paul Middleton as CFO
Subscribe for More Information
15:53 EDTBMYCredit Suisse to hold a conference
Healthcare Conference is being held in Scottsdale, Arizona on November 10-13 with webcasted company presentations to begin on November 11 at 10:30 am; not all company presentations may be webcasted. Webcast Link
13:50 EDTCSIQCanadian Solar volatility elevated into Q3 and outlook
Subscribe for More Information
08:11 EDTPTXPernix Therapeutics sees FY15 revenue $230M, consensus $214.07M
Sees FY15 adjusted EBITDA $95M.
08:11 EDTPTXPernix Therapeutics backs FY14 revenue $110M-$120M, consensus $116.87M
Sees FY14 adjusted EBITDA $22M-$24M.
08:10 EDTPTXPernix Therapeutics reports Q3 adjusted EPS (2c), consensus 0c
Reports Q3 revenue $31.5M, consensus $28.13M.
07:23 EDTPRBC Capital to hold a conference
Subscribe for More Information
07:12 EDTCSIQCanadian Solar to supply 4 MW energy storage solution to support Ontario grid
Subscribe for More Information
November 9, 2014
15:45 EDTBMYBristol-Myers announces daclatasvir data from the UNITY trial program
Subscribe for More Information
14:12 EDTRUBIRubicon Project management to meet with Needham
Meeting to be held in Boston on November 13 hosted by Needham.
12:40 EDTBMYBristol-Myers announces data from ALLY trial investigating daclatasvir
Subscribe for More Information
11:45 EDTBMYBristol-Myers announces data from the UNITY trial program
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use